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Abstract
Duchenne muscular dystrophy (DMD) cardiomyopathy patients currently have no therapeutic 
options. We evaluated catheter-based transendocardial delivery of a recombinant adeno-associated 
virus (rAAV) expressing a small nuclear U7 RNA (U7smOPT) complementary to specific cis-
acting splicing signals. Eliminating specific exons restores the open-reading frame resulting in 
translation of truncated dystrophin protein. To test this approach in a clinically relevant DMD 
model, golden retriever muscular dystrophy (GRMD) dogs received serotype 6 rAAV-U7smOPT 
via the intracoronary or transendocardial route. Transendocardial injections were performed with 
an injection-tipped catheter and fluoroscopic guidance using X-ray fused with MRI (XFM) 
roadmaps. Three months after treatment, tissues were analyzed for DNA, RNA, dystrophin 
protein, and histology. Whereas intracoronary delivery did not result in effective transduction, 
transendocardial injections, XFM guidance, enabled 30±10 non-overlapping injections per animal. 
Vector DNA was detectable in all samples tested and ranged from <1 to >3000 vector genome 
copies per cell. RNA analysis, western blot analysis, and immunohistology demonstrated 
extensive expression of skipped RNA and dystrophin protein in the treated myocardium. Left 
ventricular function remained unchanged over a three-month follow-up. These results 
demonstrated that effective transendocardial delivery of rAAV-U7smOPT was achieved using 
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XFM. This approach restores an open reading frame for dystrophin in affected dogs and has 
potential clinical utility.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is both the most common and one of the most severe 
inherited myopathies affecting up to 1 in 3500 live male births1,2. The genetically recessive 
myopathy results from mutations in the dystrophin gene, cytogenetically located on the X-
chromosome at p21.13. Dystrophin is the largest known vertebrate gene in which an 
estimated one-third of DMD-causing mutations arise spontaneously. Mutations in the 
dystrophin gene, mostly due to out-of-frame deletions, lead to loss of functional dystrophin, 
which is a critical myocyte structural protein 4.
DMD has extensive systemic manifestations and substantial morbidity5. Cardiomyopathy 
develops in nearly all patients by adulthood, at which point it confers a grave prognosis with 
a 5-year survival of 50%6,7. Medical therapy may delay the progression of the 
cardiomyopathy but has not been shown to affect mortality8,9.
One novel therapeutic approach aims to convert the out-of-frame mutation responsible for 
the disease into an in-frame mutation, thereby restoring the open reading frame and 
translation of a truncated, and presumably, quasi-functional protein. Binding anantisense 
oligonucleotide, to specific cis-acting splicing signals in the primary transcript target 
sequence, interferes with recognition of that splicing substrate resulting in deletion, or 
skipping, of one or more exons. These specific deletions, by design, restore the translational 
reading frame. The anti-sense sequence can be delivered by a recombinant adeno-associated 
virus (rAAV) that contains an expression cassette producing a small nuclear (sn) U7 RNA 
modified with a short anti-sense sequence complementary to the cis-acting splicing signals 
of the targeted exon(s) (U7smOPT). This approach was proven effective in tissue culture10, 
and in dystrophin null (mdx strain) mice11,12. Translating this proof of concept to the clinic 
requires successful demonstration of this approach in a clinically relevant, large animal 
DMD model. The golden retriever muscular dystrophy dog is the best-established large 
animal DMD model13–15. The large mass of the GRMD dogs poses significant challenge in 
terms of viral quantities and delivery approaches needed in order to achieve effective gene 
therapy.
We have developed a large-scale rAAV production process yielding a vector with dual 
canine U7 smOPT exon skipping expression cassettes (Figure 1)16, and assessed the efficacy 
of various delivery methods into the myocardium of healthy and sick animals.
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The rAAV6 was delivered to the left ventricular myocardium of the treated dogs either by 
intracoronary infusion (n=3) or by transendocardial injections (n=5). One homozygous 
female GRMD dog served as negative control and received sham injections. Both delivery 
methods were well tolerated without any hemodynamic changes or significant arrhythmias. 
Initial experience with intracoronary delivery of rAAV6 of either GFP (n=2) or U7 snRNA 
(n=1) showed minimal transduction efficiency as evidenced by low rAAV DNA in the 
myocardium. Therefore, subsequent experiments were performed using transendocardial 
injections.
X-ray fused with MRI (magnetic resonance imaging) (XFM) successfully guided the 
transendocardial injections by overlaying the myocardial contours and structures over the 
fluoroscopy images viewed by the operator (Figure 2) thus enabling 30±10 target injections 
per animal. By updating injection locations in real-time, XFM provided a 3D map for 
distributing the injections as uniformly as possible. Previously injected areas were avoided 
and untreated regions were identified and targeted enabling additional transendocardial 
injections at those locations (Figure 2). The extensive distribution of injections was 
demonstrated also by T2*-weighted MRI shortly after the injections based on the presence 
of the SPIO particles in the injected myocardium (Figure 3). Healthy animals (n=2) were 
survived for 31±3 days, and GRMD animals (n=3) were survived for 84±24 days after 
injections. The average number of injections to the basal areas was lower (1.2±1.1) than the 
mid and apical areas (2.1±1) due to technical difficulty in reaching the basal ventricle of 
small animals using an injection catheter with curves designed for larger human ventricles 
(Figure 4).
Vector DNA detection
In order to assess the efficacy of rAAV delivery we analyzed tissue samples for viral DNA. 
Vector DNA was detectable in all samples tested using nested PCR and averaged 126±346 
vg copies per cell (Figure 5). Similar to the injection distribution which was limited in the 
basal areas, larger amounts of viral DNA were found in the mid or apical segments 
(172±282 vg/cell) compared to the basal segments (41±62) (Figure 4). There was correlation 
between the number of injections in a specific segment and the numbers of vector DNA 
identified (Figure 6, r=0.789).
Dystrophin RNA detection
The RT-PCR amplified region of the native RNA transcript of dystrophin in healthy canine 
has a predicted size of 911 bp whereas in an untreated GRMD dog, the same rtPCR 
amplified region generates a product of 792 bp due to exon 7 deletion (Figure 7). Induced 
exon skipping resulting from effective rAAV transduction of GMRD created an alternative 
splicing pattern with two unique RT-PCR products appearing as 478 bp and 305 bp bands. 
In samples with effective exon-skipping, the alternative splicing resulted also in diminished 
band intensity at the 792 nt un-skipped transcript location (Figure 7). The prevalence of 
exon skipping was associated with higher number of injections and rAAV DNA (Figure 4).
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The identities of the two prominent new RT-PCR products were determined by DNA 
sequencing (Figure 8A and B). Based on the sequence analysis, the 478 bp product resulted 
from dystrophin transcripts with deletions of exons 7, 8, and 9, whereas the 305 bp product 
resulted from dystrophin transcripts that have deletions of exons 6 – 9. Although the 
additional deletion of exon 9 does not alter the dystrophin open reading frame, transcripts 
retaining exon 6, i.e. transcripts with deletions of exons 7, 8, 9, results in a reading frame-
shift that terminates translation at a nonsense codon in exon 10. However, in each sample in 
which the Δ7, 8, 9 RT-PCR product was produced the Δ6, 7, 8, 9 (reading-frame restored) 
product was also detected. Whereas, no RT-PCR products were generated corresponding to 
transcripts with Δ6, 7, 9 suggesting that the sequential order of splicing remains intact.
Dystrophin Western Blot Detection
Dystrophin protein was detected in protein extracted from treated heart samples by western 
blot analysis (Figure 9). The amount of dystrophin expressed in the treated heart samples 
corresponds to a relatively low level compared to normal heart samples. Every normal 
cardiomyocyte expresses dystrophin, however, only transduced myocytes are capable of 
dystrophin expression. The amount of dystrophin protein represents an average value of both 
transduced and untransduced cells that were present in each randomly selected sample.
Histology and Immunohistochemistry
Immunohistochemistry (IHC) using anti-dystrophin immune serum demonstrated extensive 
expression of dystrophin protein throughout the treated heart of GRMD dogs (Figure 10). 
Control GRMD dogs had no detectable dystrophin staining in myocardial samples. The 
highest levels of IHC fluorescence corresponded to the myocardial segments that had the 
highest amounts of vector DNA and were also strongly positive for exon-skipped dystrophin 
rtPCR products. T-cell infiltration into the heart parenchyma is characterized using 
hemotoxylin and eosin (H&E) staining. H&E stained sections from normal heart, untreated 
GRMD heart, and treated GRMD heart, were examined by light microscopy. Treated 
GRMD heart sections tended to have more hematoxylin stained nuclei than untreated 
GRMD sections (Supplemental Figure 1). Because the GRMD pathology involves 
inflammation and fibrosis, and due to the variability between individual animal pathologies, 
it is difficult to conclude that the vector per se caused or worsened the inflammation. 
However, we have designed future study with an immunosuppressive regimen to simplify 
the data analysis.
Left ventricular function
GRMD animals used in the present study had advanced disease with clinical 
cardiomyopathy at the time of enrollment into the study, as indicated by the impaired LV 
function at baseline (LVEF 30.4±3.6) (Figure 11). However, throughout the follow up 
period, there was no additional deterioration of the LV function (−0.4±0.8) (Figure 11). In 
accordance to the weight gain of the animals throughout the follow up period, the LVEDV, 
LVESV and SV increased (Figure 11).
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Patients who develop Duchenne cardiomyopathy currently have a grave prognosis with no 
therapeutic options. We therefore evaluated a novel exon-skipping gene therapy approach 
for the treatment of Duchenne cardiomyopathy. This pre-clinical study was performed in 
GRMD canines which are the closest animal model prior to translation into clinical research. 
An injection catheter was introduced into the left ventricular cavity by means of 
percutaneous arterial access. This catheter was used retrograde across the aortic valve to 
deliver rAAV6-U7smOPT into the myocardium using MRI roadmaps co-registered with live 
X-ray fluoroscopy. This approach allowed wide transendocardial distribution of the 
injections, induced extensive exon skipping and rescued dystrophin expression in the 
diseased cardiomyocytes.
As a monogenic recessive disease, DMD is an attractive target for gene-based therapy. 
However, several aspects of DMD in particular, create challenges in developing effective 
gene therapy approaches. The large size of the dystrophin gene (approximately 2.5 Mbp) 
and the resulting mRNA of the full-length protein (approximately 12 knt) 4 preclude 
standard “gene” replacement approaches. An AAV-based approach to deliver mini- or 
micro- dystrophin cDNAs which can produce a truncated, but functional dystrphin protein, 
face difficulties because the size of the cDNAs exceed the length of wild-type AAV 
genomes resulting in less efficient vector genome encapsidation and poor vector yields. 
Exon-skipping provides an alternative approach for restoring the dystrophin open reading 
frame. This process blocks transcript and exon specific cis-acting recognition signals 
consisting of intronic elements (pyrimidine tract, branch point, etc.), or exonic splice 
enhancer element, and canonical splice donors and acceptors 17–21. Thus, by targeting a 
specific splicing signal with the complementary element, one or more exons may be deleted, 
or skipped, thereby restoring the translational reading frame. Initially developed using 
synthetic antisense oligonucleotides (AON), exon skipping has been adapted as a component 
of small nuclear RNAs (snRNA), either the spliceosomal U1 snRNA or a modified U7 
snRNA that interacts with the spliceosome, U7 smOPT22. By introducing a short, 
complementary sequence into the 3’-end of the snDNA, the transcript can target a specific 
splicing signal in the dystrophin pre-mRNA. This approach is currently undergoing clinical 
evaluation 23–25. Although the cellular pathways for salvaging or degrading polynucleotides 
do not metabolize synthetic oligonucleotides, these oligonucleotides do not persist 
indefinitely either intracellularly or systemically. Thus, this approach requires repeated, 
systemic administrations. To overcome this limitation an alternative approach has been 
developed in which the snRNA expression cassette has been engineered into recombinant 
adeno-associated virus vector genome (rAAV). This approach was proven effective in 
skipping a single exon and restoring dystrophin expression in the mdx mouse, which due to 
a transition in exon 23, a stop codon prematurely terminates translation11,12.
While myocardial gene therapy demonstrated promising results in small animal models 26, 
translating these methods into large animal models and humans has been non-trivial. Several 
approaches to achieve effective transduction of the myocardium have been tested and 
reported with varying degrees of success in terms of histologic or phenotypic effects. 
Intracoronary infusion of the desired vector seems to be the most promising approach but 
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has yielded varying results 27–29. To improve efficiency rates, several improvements have 
been proposed including retroinfusion of the vector through the coronary veins 27 or cardiac 
recirculation of the delivered vector 30. In the present study we failed to achieve detectable 
cardiomyocyte transduction following intracoronary infusion of the vector with proximal 
flow occlusion. Based on initial experience of transendocardial delivery of viral 
vectors 31–33 we have pursued a related approach. However, as the left ventricular cavity is a 
complex three dimensional structure an appropriate approach to efficiently target all 
myocardial locations would require guiding by an imaging modality that would be able to 
depict three-dimensional structures. Bish et al. 31,34 performed rAAV transendocardial 
injections with fluoroscopic guidance, this allowed 2-dimenstional guidance without the 
ability to identify any ventricular structures such as the papillary muscles or valves. While 
demonstrating efficient gene transfer in two areas (septum and left ventricular free wall), the 
robustness of the distribution with such approach is unknown. To address this limitation we 
used an advanced multimodality imaging methodology that combines MRI-derived contours 
of region of interest and overlaid these contours on top of the standard fluoroscopic views, 
these merged images accurately represented the relevant cardiac structures. This approach 
allowed accurate guidance and real-time assessment of injection locations. Indeed, in the 
present study, basal areas were less effectively targeted; however this limitation is attributed 
to sub-optimal catheter shapes which are intended for use in humans.
In the present study, three months post-treatment, the effects of vector-mediated exon-
skipping were evident. The concentration of vector DNA in randomly selected samples 
ranged from 981 to less than 1 vg/cell and dystrophin expression was restored efficiently. As 
anticipated, there was good correlation between the amount of injections and the viral DNA 
in the tissue, however, because the DNA processed for PCR and RNA processed for rtPCR 
were extracted from different specimens, the exon-skipped RNA and vector genome copy 
numbers results did not correlate.
Using large-scale rAAV production, we were able to evaluate two routes of administration 
for treating dystrophic dogs. This capability is essential for translating treatments from small 
animal proof-of-concept studies to demonstrating feasibility in a clinically relevant, large 
animal model of DMD.
The phenotypic effect of this exon skipping gene therapy was modest, demonstrating stable 
left ventricular function without any significant improvement in three months follow up. The 
treated GRMDs were relatively old (7–11 months old), had advanced systemic disease, 
demonstrating dramatic muscle wasting, weakness and some required percutaneous 
gastrostomy feeding due to impaired swallowing mechanism and recurrent pulmonary 
aspiration of gastric contents. Accordingly, all had advanced cardiomyopathy with impaired 
LV function at the time of treatment. It is conceivable that even the most effective treatment 
would not be able to reverse LV dysfunction in this set of animals. Thus, the present results 
which demonstrate prevention of further deterioration in LV function might be viewed as 
encouraging results.
The present study has several limitations. Our attempts to deliver the rAAV via the coronary 
approach failed. It is possible that supplementing our techniques with the previously 
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reported methods 27,30 might have increased the efficiency of gene transfer via the 
intracoronary approach. The rAAV6-U7smOPT vector restored dystrophin expression in 
most samples tested. Distributing the injections uniformly throughout the LV myocardium 
and prolonging the dwell time for each injection is difficult without inducing cardioplegia. 
Thus, it is conceivable that subsequent to withdrawing the needle from the injection site, the 
vector refluxes along the needle track and does not diffuse interstitially35. Despite the high 
doses of concentrated rAAV6-U7smOPT, it is likely that the heart contractions caused 
leakage of the vector back into the ventricular cavity, thereby limiting the amount of vector 
remaining in situ. Finally, due to the difficulty in breeding and availability of GRMD 
canines, the number of GRMD canines that were used in this study was relatively small. It is 
possible that lager number of animals and longer follow-up would have yielded more 
meaningful phenotypic data. No control dogs were used for comparison in the functional 
studies.
METHODS
Animals and study design
Animal procedures were approved by the institutional Animal Care and Use Committee and 
performed according to contemporary National Institutes of Health guidelines. A total of 
nine dogs were used, including four normal male beagles (11.9±1.1 kg) and five affected 
GRMD dogs (four male and one homozygous female) (12.1±3.1 kg). Of these, three dogs 
(two normal dogs and one GRMD dog) received intracoronary rAAV infusion, five (two 
normal dogs (beagles) and three GRMD dogs, same sire different dames) received 
transendocardial rAAV delivery and one homozygous female GRMD dog served as control 
(alittermate an experimental GRMD affected male dog). Animals were pretreated by oral 
amiodarone, atenolol and prophylactic cefazolin. Anesthesia was induced by midazolam, 
propofol and butorphanol and was maintained by sevoflurane inhalation and fentanyl 
infusion.
Vascular femoral access was achieved with a 4-Fr micropuncture kit followed by insertion 
of 6- or 8-Fr and 5-Fr sheaths in the right femoral artery and vein respectively. Vascular 
hemostasis was achieved by manual pressure and application of D-stat Dry (Vascular 
Solutions, Minneapolis, MN).
Bivalirudin (Angiomax, The Medicines Co., Parsippany, NJ) was used as a procedural 
anticoagulant due to the affinity of AAV6 capsids with heparin that effectively neutralizes 
the biological activity of rAAV vectors36,37. An initial bolus of 0.75 mg/kg was followed by 
continuous infusion of 1.75 mg/kg/hr adjusted to maintain an activated clotting time 
(Hemotec) > 250 seconds.
Treated animals were survived up to three months after the procedure. Immediately 
following euthanasia, hearts were explanted and were sliced systematically in a predefined 
mode through the short axis of the left ventricle into 17 segments at the basal (Segments 1–
6), mid-cavitary (Segments 7–12), apical (Segments 13–16) and apical cap (Segment 17), 
according to standardized segmentation of the left ventricle 38. Random samples were taken 
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from each segment and fresh frozen (−80°C) in cryopreservation medium (Tissue-Tek 
O.C.T. compound, Sakura, The Netherlands).
Adeno-associated virus vector
Recombinant adeno-associated virus serotype 6 (rAAV6) was produced in Spodoptera 
frugiperda (Sf9) insect cells using recombinant baculovirus expression vectors (BEV) as 
previously described 39. Briefly, cells were cultivated in a 250 liter single-use bioreactor 
(200 liter working volume) in serum-free insect cell medium (SFX Insect Cell Medium, 
HyClone, Logan, UT) at 28° C with 30% dissolved O2 (dO) (Integrity PadReactor, ATMI 
Lifesciences, Bloomington, MN). Temperature and dO set points were maintained during 
cell growth and vector production with control loops responding to outputs from the 
appropriate probes (TruViu and TruLogic Control System, Finesse Solutions, San Jose, CA). 
Late log-stage Sf9 cells from shake-flasks were diluted into the bioreactor’s minimum 
working volume (40 liters) and expanded to the target volume by serial dilution to the final 
working volume (200 liters). Two BEVS were required for rAAV production: one BEV for 
AAV-2 rep proteins and AAV6 cap proteins and the second BEV provided the ITR-bearing 
vector genome. Rather than using free, extracellular BEVS in solution for rAAV production, 
a pre-determined amount of concentrated, cryopreserved baculovirus infected insect cells 
(BIIC) were added to the 200 liter culture (BIIC : producer cell = 1:1000 ). The producer 
cells continued to divide until baculovirus cell cycle arrest occurred at the target cell density 
of ≈5×106 cells/ml. The downstream process for rAAV purification involved the following 
series of steps as previously described 39; Homogenization, nuclease digestion, clarification 
and microfiltration, immunoaffinity column chromatography, tangential flow filtration for 
concentration and diafiltration and final filtration and sterile dispensing into single-use vials. 
Depending on the homogeneity of the vector, gel exclusion chromatography step was 
performed (Superdex 200, GE LifeSciences).
The vector particles, consisting of AAV6 capsid proteins and a linear single-stranded DNA 
genome were characterized for composition and quantity. Following immunoaffinity 
chromatography, the vector genome concentration was determined by two methods: 
Polymerase chain reaction (PCR) using vector specific oligonucleotide primers, and by 
SYBR gold fluorescent dye binding to the vector-extracted DNA. Tangential flow filtration 
was used to achieve the final vector concentration and buffer exchange into PBS (Pellicon 2, 
Millipore Corp., Billerica, MA). The protein composition of the AAV6 capsid: VP1, VP2, 
and VP3, was analyzed by SDS - polyacrylamide gel electrophoresis (SDS-PAGE) and 
silver staining (Pierce Thermo Fisher Scientific, Rockford, IL).
The vector genome has two cassettes, each consisting of a U7snRNA promoter, a modified 
U7snRNA (U7smOPT), and short sequence complementary to the exonic enhancement 
element (ESE) of exons 6 and 8 10. The terminal palindromes were derived from AAV2. 
(Supplemental Table 1, Figure 1).
Intra-coronary delivery
Coronary injections were performed in anticoagulant-treated animals during balloon 
occlusion to delay washout. Engaging coronary arteries in these small animals required 5Fr 
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short pediatric transfemoral diagnostic catheters (JL1.5-2.0, Merrit Medical, South Jordan, 
UT). The left anterior descending and circumflex coronary arteries were injected separately 
using over-the-wire coronary angioplasty balloons (2.0–3.0mm diameter × 8.0–12.0mm as 
needed) and 0.014” coronary guidewires positioned in the mid left anterior descending or 
proximal circumflex segments. Preconditioning of the left ventricular myocardium (to help 
the animal tolerate prolonged ischemia) was accomplished by two consecutive cycles of two 
minute ischemia by coronary balloon inflation followed by five minute reperfusion (balloon 
deflation). Next, the solution containing the AAV vector (2ml × 3.5 × 1013 copies / ml) was 
delivered through the coronary balloon catheter lumen while inflating the balloon to occlude 
distal coronary artery flow (5 minutes). The same protocol was followed for the second 
vessel.
Transendocardial delivery
Transendocardial injections were performed under fluoroscopic guidance using X-ray fused 
with MRI (XFM). Injections were performed using a 7-Fr endomyocardial 27G injection 
needle catheter (Stiletto, Boston Scientific, Natik MA) 40. The Stiletto catheter was steered 
retrograde across the aortic valve inside the left ventricular cavity by means of two coaxial 
guiding catheters (8-Fr and/or 6-Fr IMA and JR guiding catheters) (Vista Brite-Tip, Cordis 
Corp., Bridgewater, NJ). The endocardium was injected repeatedly (0.2 ml per site × 20–40 
sites for each procedure) with the intention to distribute the vector homogenously 
throughout the left ventricular myocardial mass. No attempts were made to inject into the 
right ventricle free wall.
The injection cocktail included virus and both MRI and X-ray contrast agents. Each 200µl 
injection was comprised of ≈1.5 ×1013 vg rAAV stock (1014 vg/ml), 50 µg of 
supraparamagnetic iron oxide particles (SPIO) (50mg/ml stock, BioMag 547, Bangs 
Laboratories Inc., Fishers IN), and 50µl iopamidol, a fluoroscopy contrast agent (Isovue 300, 
Bracco Therapeutics, Princeton, NJ). The control dog received identical solution; however 
the viral volume was replaced by saline. The delivery of this solution enabled correlation 
between real-time localization of the injection sites under XFM (iopamidol) with 3-
dimensional, anatomic, early post-procedural analysis of the injections according to the 
SPIO particles void signal in T2* weighted MR images.
We were careful to identify, record and verify each injection site in order to distribute the 
virus widely. Because the injectate contained iopamidol, the 3D position of each injection 
was recorded under XFM to avoid overlap. The injectate also included SPIO MRI contrast, a 
MRI scan immediately after injections showed a complementary image of injections 
throughout the heart. Finally, these images were compared with histopathology.
X-ray fused with magnetic resonance imaging
XFM combines pre-acquired 3-dimensional MR image roadmaps of anatomic structures (the 
left ventricular myocardium in this experiment) and standard X-ray fluoroscopy images that 
provide high resolution images of the injection catheter and radiocontrast. This co-
registration, or fusion enables 3-dimensional targeting of injections into soft tissue that is 
otherwise not visible using X-ray alone.
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For XFM we combined MRI volumes of the heart and X-ray fluoroscopy as previously 
described 41. Briefly, a set of external fiducial multimodality markers (Beekley, Bristol, CT) 
were placed on the animal’s chest and back. T1-weighted gradient echo MR images and a 
set of X-ray fluoroscopy projections were used to register the two modalities. Relevant 
cardiac structures (e.g. left and right ventricles, aorta) were segmented from MR images and 
projected onto live X-ray fluoroscopy for real-time XFM guidance. Fusion images were 
displayed alongside live X-ray images on an external monitor. During the procedure 
injection sites were marked on two different X-ray projections and displayed on the fusion 
images as well as a 3D model of the heart.
Magnetic resonance imaging
Scans were performed in a 1.5T MRI scanner (Espree, Siemens Medical Solutions, 
Erlangen, Germany) using surface phased array receiver coils. Geometric and functional 
measurements of the LV used ECG-gated, segmented, breath-held, balanced steady state 
free precession (bSSFP) sequences incorporating parallel imaging with an acceleration 
factor of two, repetition time (TR)/echo time (TE) 3.2/1.4 ms; flip angle 80°; field of view 
(FOV) 300 × 300 mm; matrix 192 × 192 pixels; slice thickness 6 mm; bandwidth 930 Hz/
pixel. Argus Function software (Siemens Medical Solutions) was used to calculate LV 
ejection fraction (I.M.B.). T2*-weighted, FLASH sequence with TR/TE 6.6/3.5 ms; flip 
angle 15°; FOV 250 × 160 mm; matrix 192×125 pixels; slice thickness 6mm; bandwidth 260 
Hz/pixel was used to identify injection sites by means of the SPIO iron-induced signal voids. 
Images were analyzed using a commercial cardiac MRI workstation (Argus, Siemens).
DNA analysis
Total DNA from a random sample from each of the 17 pre-defined myocardium segments 
was isolated and purified using Gentra Puregene kit (Qiagen, Valencia, CA) according to the 
manufacturer's instructions. PCR reactions were performed as described previously 42. 
Products were analyzed on ethidium bromide stained 2% agarose gels and sequenced. Six pg 
per diploid genome was used to calculate the vector copy number per cell using 2.5 × 109 bp 
× 2 as the approximate size of the canine diploid genome.
RNA analysis
Total RNA from each of the 17 pre-defined myocardium segments was extracted from 
randomly sampled specimens using a commercially available kit (RNeasy, Qiagen, 
Valencia, CA). The RNA was reverse transcribed to cDNA using Superscript I or II (RT) 
system (Invitrogen, Carlsbad, CA). Canine dystrophin specific exon 3 and exon 10 primers 
were for the reaction at 55°C for 30 minutes. The RT reaction was used for nested PCR 
reactions: First using a pair of external primers, and subsequently, with a pair of internal 
primers. The forward primers (F) for both external and internal primers were in exon 3 and 
the reverse primers (R) were in exon 10. External primers 42: F 
5’GGAAGCAGCACATAGAGA; R 5’ TCACTTCTTCGACATCATTAG. Internal 
primers: F 5’ GAGACGCCTCCTAGACCT; R 5’ TCACTTCTTCGACATCATTAG. The 
PCR reactions were analyzed using ethidium bromide stained agarose gel electrophoresis. 
The open reading frames of the the isolated PCR products were determined by DNA 
sequence analysis
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To increase the sensitivity of detecting the dystrophin mRNA, nested PCR using “outer” and 
“inner” set of primer pairs were used following reverse transcription of extracted 
cardiomyocyte RNA. Both sets of primers, specific to dystrophin exons 3 and 10, amplified 
the region targeted by the exon-skipping vector. The predicted sizes of the wild-type and 
GRMD (Δ7) rtPCR products are 911 bp and 792 bp, respectively (Figure 3, “Normal Dog” 
and “GRMD dog untreated” lanes). The rAAV-U7smOPT vector was designed to induce 
skipping of exons 6 and 8 generating a Δ6, 7, 8 transcript with a predicted size of 437 bp. 
However, exon 9 deletion occurs cryptically producing a Δ6, 7, 8, 9 dystrophin rtPCR 
product that is 305 nt.
Dystrophin western blot analysis
Western blot analyses were performed on total protein extracted from previously frozen 
O.C.T. embedded heart segment sections (10 µm thickness) mounted on uncoated glass 
slides. Protein was extracted using a modified SDS-protein gel loading buffer as previously 
described consisting of 4% SDS, 125 mM Tris-HCl (pH 8.8), 40% glycerol, 
phenylmethylsulfonyl fluoride (0.5mM), and 100 mM dithiothreitol 43. Equivalent volumes 
of the protein extracts were fractionated using pre-cast polyacrylamide gradient gel 
electrophoresis (NuPAGE Tris-Acetate SDS polyacrylamide gels, Invitrogen, Inc.) and 
electrophoretically transferred to polyvinylidene fluoride (PVDF) membranes in transfer 
buffer (NuPAGE Transfer Buffer) containing 20% methanol (constant 30V, overnight at 
4°C). Protein loads were adjusted by digital analysis of common protein bands in Coomassie 
blue stained gels. Standard western blot conditions were used for membrane blocking, 
washing, staining, and chemiluminescence. Blocking buffers (BB): PBST - phosphate 
buffered saline (PBS = 50 mM Tris-HCl (pH 7.6) and 150 mM NaCl), 0.1% Tween-20, and 
5% non-fat dry milk (w:v) (BB1) and BB2, PBST with 5% bovine serum albumin (BSA)
(w:v). Washing buffer: phosphate buffered saline and 0.1% Tween-20. Chemiluminesence 
reagent: SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). After 
blocking the membranes (30 min at ambient temperature), the primary antibodies were 
diluted and added to the BB solutions. The anti-dystrophin-peptide antibody (rabbit 
polyclonal) (ab15277, Abcam Inc., Cambridge, MA USA) was diluted 1:200 in BB1, and 
incubated overnight at 4° on a rocking platform platform. Following incubation, the 
membranes were washed in the BB1, 3 × 10 min at room temperature, and the diluted 
secondary antibody, 1:5,000 goat anti-rabbit IgG – horse-radish peroxidase (HRP) (A5278, 
Sigma-Aldrich), was added to the BB1 for 1hr at room temperature with agitation. The 
solution with the secondary antibody was removed and the membrane was washed in PBST 
(3 × 10min). After the final wash, the luminol substrate was added (SuperSignal West Dura 
Extended Duration Substrate, Thermo Scientific) and the chemiluminescence signal was 
detected using a charged-coupled device (CCD) camera and digital imaging processor 
(G:BOX Chemi, Syngene, Frederick, MD USA). The data were analyzed using software 
(Gene Tools) provided with the imaging system.
Immunohistochemistry and histology
Tissue specimens were sectioned using a cryostatic microtome into 5 to 10µm thick slices 
and mounted onto silane–treated glass slides and fixed with 10% formalin for 10 minutes at 
room temperature then washed (3x) in phosphate buffered saline (PBS). For IHC, the 
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formalin-fixed tissue sections were incubated in blocking buffer with either 5% goat serum 
or 5% bovine serum diluted in PBS, depending on the primary antiserum source, for 30 
minutes at ambient temperature. The blocking buffer was removed and primary antiserum 
was applied. For dystrophin detection, a rabbit polyclonal antiserum (ab15277, Abcam) was 
diluted (1:1000) into fresh 2% goat serum in PBS and applied to the section and incubated 
overnight at 4°C in a humidified chamber. The antibody solutions were removed and the 
samples were washed with PBS (3x) at room temperature. Fluorescently labeled secondary 
antibodies were diluted in bovine serum - PBS and applied to the samples and incubated at 
room temperature for one hour in a dark plastic chamber to exclude light. The antibody 
solutions were then removed and washed with PBS. Coverslip mounting medium was 
applied (Vectashield Mounting Medium with DAPI) (Vector Laboratories Inc.) and a 
coverslip was placed over the tissue sample.
Data analysis
Statistical analysis used InStat (GraphPad Software, Inc., La Jolla, CA). Continuous 
parameters are reported as mean ± standard deviation, tested using two-tailed paired t-test. A 
p value less than 0.05 was considered significant. Correlation between number of injection 
and presence of viral DNA was assessed by Spearman’s rank correlation test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Diagram of the rAAVU7 smOPT E6E8 vector genome
The 1303 nt single-stranded rAAVU7smOPT E6E8 vector genome is represented 
schematically. The AAV type 2-derived ITRs are represented by rectangles with diagonal 
slashes. The two U7smOPT expression cassettes are identical except for the short anti-sense 
sequences complementary to the exon 6 and exon 8 exon splice enhancers (ESE) of the 
canine dystrophin gene (vertical and horizontal slashes, respectively). Sequences 
homologous to the non-coding murine U7 snRNA are represented by rectangles labeled 
“U7” and the positions of the smOPT modification are indicated.
Barbash et al. Page 15













Figure 2. Transendocardial injections locations on X-ray fused with MRI (XFM) images
X-ray fused with MRI (XFM) overlays heart contours and structures onto X-ray 
fluoroscopy. In multiple projections this provides 3-dimensional orientation and guidance 
for transendocardial injections. In (A) a short axis and long axis (B) views of the heart are 
demonstrated with the XFM contours overlaid on the fluoroscopy. The green contour 
represents the left ventricular endocardium, orange represents the right ventricular 
endocardium, blue lines indicate the mitral valve, and red lines indicate the location of the 
aortic valve.
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Figure 3. Locations of the rAAV-U7smOPT and the SPIO particles in the left ventricular 
myocardium
Representative images of 2-chamber (A), 3-chamber (B) and 4-chamber (C) T2*-weighted 
MRI immediately following the injection demonstrating wide distribution of the injections 
throughout the left ventricular wall. Arrows point to MRI signal voids, which reflect SPIO 
particles included in the virus injection mixture.
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Distribution of injections, viral DNA and exon-skipped RNA following transendocardial 
delivery of rAAV6-U7smOPT. Panel A maps the myocardial segments numbering; The 
basal slice is represented by segments 1–6, the mid-ventricular slice is represented by 
segments 7–12, the apical slice is represented by segments 13–16 and the apical cap is 
represented by segment number 17. Panel B: Average ± standard deviation of injections per 
segment. Panel C: Amounts of viral DNA (Vg) per cell in myocardial segments 1–17. Panel 
D: Samples from all segments were analyzed for presence of alternative splicing. In this 
panel, the percentage of positive samples for alternative splicing is reported for each 
segment.
Barbash et al. Page 18













Figure 5. Presence of viral DNA in the various myocardial segments
Demonstrated is a representative agarose gel analysis of a sample from each of the 17 
myocardial segments (including 2 samples from segment 17, a+b) and a negative control 
from an untreated GRMD dog. This panel demonstrates a 500 base-pair PCR product on an 
ethidium bromide gel in the majority (13/17) of the sampled myocardial segments.
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Figure 6. Correlation between the numbers of injections per myocardial segment and the 
amount of viral DNA
As demonstrated, a higher number of injections per myocardial segment correlated with 
larger amounts of viral DNA (vg/cell) (r=0.789).
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Figure 7. Sizes of dystrophin gene RNA transcript in the various myocardial segments
Sample from “Normal dog” demonstrate the predicted RNA transcript size band at 911 base-
pair (bp) whereas an “Untreated GRMD dog” (natural occurrence of exon 7 skipping) 
produce a typical band at 792bp. The predicted size of bands for the in-frame skipping of 
treated dog with U7-ESE6/8 construct is 437bp for skipping of exons 6 to 8 and 305bp for 
skipping of exons 6 to 9. In the presented representative gel, two dominant new bands 
appear in samples 2, 4, 5, 8–12 and 16 of the treated dog. The lower band (300bp) 
corresponds to an in-frame skipping of exons 6 to 9, whereas the upper band (500pb) 
represents a non in-frame skipping.
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Figure 8. Purification and sequencing of nested RT PCR product
(A) The in-frame and the non in-frame skipping band have been extracted from the gel and 
were sequenced using the inner primer exon 3 and the inner primer exon 10 (purification 
band #1). (B) Sequences analysis demonstrate that the lower band (305bp) corresponds to 
skipping of exons 6 to 9 with restoration of open reading frame whereas the upper band 
(478pb) corresponds to skipping of exons 7 to 9 which did alter the open reading frame.
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Figure 9. Western blot analysis of heart protein
Soluble protein extracts prepared from randomly selected 20µm thick frozen sections were 
fractionated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF 
membrane. The heart segments are indicated and the positive control consists of 5% normal 
dog heart protein extract in untreated GRMD heart protein extract. The negative control 
(lane 1) is untreated GRMD heart protein. The low level dystrophin protein signal was 
observed reproducibly and is likely the result of the so-called “revertant” myocytes in the 
GRMD dogs. Presumably, aberrant splicing restores the dystrophin open reading frame in a 
relatively small percentage of cells resulting in a natural form of exon skipping.
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Figure 10. Immunohistochemical staining to dystrophin proteins in GRMD canines treated with 
rAAV-U7smOPT
(1–17) Slides 1 to 17 (excluding slide 6) demonstrate various levels of positive staining for 
dystrophin in samples collected randomly from each of the 17 pre-defined left ventricular 
myocardial segments. The positive staining is typically located at the cell membrane, 
corresponding to the location of the functional dystrophin protein. As controls, tissues from 
(18) normal dog (positive control) and (19) untreated GRMD dog (negative control) were 
used. All images were acquired at a 20X magnification. The scale bars represents 50 µm.
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Figure 11. Left ventricular size and function at baseline and 3 months follow-up
Left ventricular size and function were evaluated by cardiac MRI at baseline and at 3 
months follow-up. As demonstrated, left ventricular ejection fraction remained unchanged 
during the study period. During the study period, left ventricular volumes and stroke 
volumes increased as the juvenile animals grew in size.
EF – Ejection fraction, LVEDV – Left ventricular end diastolic volume, LVESV – Left 
ventricular end systolic volume, SV – Stroke volume
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